 |
Joe Barton (ed). Witnesses: Joseph Camardo, Sr. V.P., Wyeth Pharmaceuticals; Cathryn Clary, U.S. Medical, Psychiatry & Neurology, Pfizer, Inc.; Ronald Davis, member, ARA Board of Trustees; Richard Gorman, American Academy of Pediatrics; John Hayes, Product Team Leader, Eli Lilly Co.; Caroline Loew, V.P., Scientific & Regulatory Affairs, PhRMA; Ronald Marcus, Neuroscience Global Clinical Development, Bristol-Myers, Squibb Co.; Larry Olanoff, Exec. V.P., Scientific Affairs, Forest Labs., Inc.; Patrick Osinsky, General Counsel, Organon USA; David Wheadon, Sr. V.P., Regulatory Affairs, GlaxoSmithKline; & Janet Woodcock, Dep. Comm. for Operations, FDA. Additional material: FDA, letter to John Eingell; & FDA, response. Illustrations.
|
|
|
